Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone + bupivacaine
- Development stage
- Unknown
- Lead developer
- Pacira BioSciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intraarticular, Epidural, Local Infiltration, Soft Tissue Infiltration, Intrabursal, Periarticular
01
Overview
Triamcinolone + bupivacaine is a combination of two pharmaceutical agents used primarily for the management of pain and inflammation, especially in perioperative or post-surgical settings. Triamcinolone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties, acting by modulating gene expression to suppress pro-inflammatory cytokines and mediators. Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels on neuronal membranes, inhibiting nerve impulse transmission to provide local or regional anesthesia. The combination leverages the rapid onset analgesia of bupivacaine with the prolonged anti-inflammatory effects of triamcinolone, resulting in improved pain control compared to either agent alone[1][2]. This mixture has been studied for use in procedures such as lumbar discectomy and intra-articular injections.
- Brand names
- Kenacort
- Other names
- triamcinolone acetonide + bupivacaineAdcortyl + Marcaine
02
Targets
GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on triamcinolone + bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone + bupivacaine.